Company Website:
http://www.johnsonandweaver.com
SAN DIEGO -- (Business Wire)
Shareholder rights law firm Johnson & Weaver, LLP continues its
investigation into whether certain officers and directors of Biota
Pharmaceuticals, Inc, (Nasdaq: BOTA) violated state or federal laws.
Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the
discovery and development of anti-infective products.
On August 1, 2014 Biota announced its experimental influenza drug failed
to meet the main goal in a mid-stage study. In April 2014 the U.S.
Department of Health and Human Services pulled out of a contract to
support the drug's development. The contract provided up to $231 million
in financial support for the development of laninamivir octanoate for
the treatment of influenza A and B in the United States.
If you have information that could assist in this investigation,
including former employees and others, or if you are a Biota shareholder
and are interested in learning more about the investigation or your
legal rights and remedies, please contact Jim Baker (jimb@johnsonandweaver.com) by
email or by phone at 619-814-4471.
About Johnson & Weaver, LLP:
Johnson & Weaver, LLP is a nationally recognized shareholder rights law
firm with offices in California, New York and Georgia. The firm
represents individual and institutional investors in shareholder
derivative and securities class action lawsuits. For more information
about the firm and its attorneys, please visit http://www.johnsonandweaver.com.
Attorney advertising. Past results do not guarantee future outcomes.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151009005694/en/
Contacts:
Johnson & Weaver, LLP
Jim Baker, 619-814-4471
jimb@johnsonandweaver.com
Source: Johnson & Weaver, LLP
© 2024 Canjex Publishing Ltd. All rights reserved.